ProShares Ultra Nasdaq Biotechnology Rating $55.43 +0.78 (+1.43%) As of 03:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.70Holdings in BIB have an aggregate rating of Moderate Buy based on 334 analyst ratings issued in the past year covering 19 companies (37.0% of the portfolio).BIB Aggregate Price Target$55.31-0.08% DownsideHigh Prediction$55.31Average Prediction$55.31Low Prediction$55.31Holdings in BIB have an aggregate price target of $55.31 and a range of $55.31 to $55.31 covering 19 companies (37.0% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.60%GILDGilead Sciences$114.24+0.1%4.9812 of 5 stars2.88$115.39 1.0%26Positive News4.50%AMGNAmgen$289.10+0.2%4.7301 of 5 stars2.33$304.43 5.3%21Trending NewsAnalyst Forecast3.96%REGNRegeneron Pharmaceuticals$583.43+1.9%4.8493 of 5 stars2.81$829.65 42.2%26Positive News3.95%VRTXVertex Pharmaceuticals$387.47-0.4%4.9563 of 5 stars2.56$497.10 28.3%27Positive News3.30%ALNYAlnylam Pharmaceuticals$448.62+1.1%4.1233 of 5 stars2.85$405.33 -9.6%263.05%AZNAstraZeneca$79.98+0.4%2.7842 of 5 stars2.80$86.00 7.5%5Positive News1.53%INSMInsmed$131.03+2.1%3.9701 of 5 stars2.94$132.57 1.2%171.33%ARGXargenex$703.17+3.8%3.2783 of 5 stars3.10$763.47 8.6%21News CoveragePositive NewsAnalyst ForecastGap Up1.30%BIIBBiogen$136.300.0%4.8341 of 5 stars2.34$185.74 36.3%32Trending News1.24%SMMTSummit Therapeutics$26.85+2.2%1.5451 of 5 stars2.63$32.85 22.4%16Gap Up1.05%INCYIncyte$83.93-1.0%4.7038 of 5 stars2.33$81.60 -2.8%181.03%ILMNIllumina$98.90-0.8%4.8614 of 5 stars2.25$124.58 26.0%20Positive News0.98%RPRXRoyalty Pharma$35.81-0.5%4.9774 of 5 stars3.33$48.00 34.0%3News CoveragePositive News0.92%SNYSanofi$50.22+0.2%3.7884 of 5 stars3.11$62.00 23.5%9Positive News0.90%UTHRUnited Therapeutics$306.47+0.4%4.9216 of 5 stars2.69$382.00 24.6%13Positive NewsAnalyst Revision0.86%TEMTempus AI$74.94-1.3%2.0632 of 5 stars2.50$67.64 -9.7%120.86%NBIXNeurocrine Biosciences$136.56+1.9%4.859 of 5 stars2.86$159.50 16.8%21Positive News0.85%MEDPMedpace$467.81+0.2%4.3119 of 5 stars1.93$406.60 -13.1%14Positive News0.83%ONCBeOne Medicines$307.00-0.5%0.5624 of 5 stars3.00$330.89 7.8%7News Coverage This page (NASDAQ:BIB) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access